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BODY:
The biology of disease progression in CML is incompletely understood. Several genetic lesions have been linked with progression, including loss of tumor suppressors p16, Rb or p53.
Importantly, disease progression is often associated with a reduced effectiveness of imatinib therapy. However, in the chronic phase of CML most cases of resistance can be explained by Bcr-Abl point mutations (2) , the increase in drug resistance upon progression can not be explained by these mutations, in fact in some studies refractory cases in advanced disease stages show a lower frequency of Bcr-Abl mutations (3) . These clinical data suggest, that factors associated with or directly involved in disease progression may impact imatinib therapy. Our work addresses the role of genetic changes in disease progression and explores their impact on imatinib response -ultimately this might open new therapeutic opportunities.
We proposed to conduct an in vivo RNAi screen in the Tec p210 transgenic mouse, a long latency model of chronic myeloid leukemia (4) , to identify genetic lesions that would cause acceleration and a more aggressive pathology. In a second study, we would then study the impact of these lesions on imatinib response. Using a highly innovative technology, we put great emphasis on accurate positive and negative controls. Loss of p53 has been shown to cause disease acceleration in the Tecp210 CML model (5) .
We initiated experiments to confirm the effect of p53 loss in a retroviral model of CML (6) . Basically, we transduced hematopoietic stem cells (HSCs) of different p53 status with a Bcr-Abl expressing retroviral vector (see Appendix: Wendel et al., Fig. 2A) . Briefly, we found some acceleration of disease onset and variable effects on the pathological appearance (see 6 ). This reduced imatinib effect is important, because inactivation of p53 has been reported in up to 1/3 of patients with advanced disease -thus, while not identified in the proposed screen p53 appeared to be exactly what we were looking for and we decided to follow this lead.
As resistance to imatininb had mostly been attributed to impaired drug-target interaction and consequently reduced kinase inhibition, we first wanted to ascertain equal BCR-ABL inhibition by imatininb in mice with p53+/+ and p53-/-leukemias. Looking at both direct and indirect targets of BCR-ABL signaling, p62Dok and ribosomal S6 protein, respectively, we found equal effect of the drug on kinase activity (Appendix: Wendel et al., Fig. 3D ). Indicating, that lack of response was due to a post-target mechanism.
Next, we wanted to validate our in vivo findings using an established in vitro system of Bcr-Abl mediated transformation. We chose 32D and Baf/3 cell lines, but also looked at Fig. 2) . Along with colony formation data (Fig. 2C) , these findings indicate that the tumor suppressor p53 contributes to imatinib action at least in part through a cell-intrinsic effect and resistance in vivo is not merely a reflection of a more aggressive pathology.
Then we wanted to understand the effect of BCR-ABL inhibition on p53. We found that Strikingly, Akt mediated activation of Mdm2 as mediated by a S166 phosphorylation was sharply reduced upon imatinib treatment in vitro. A direct effect on Mdm2 levels was not observed (7) (Appendix: Wendel et al., Fig. 1B) . Clearly, the interaction between Bcr-Abl and p53 is more complex, however, these findings suggest a mechanism for the observed p53 activation as a consequence of inhibiting signals emanating from the BCR-ABL kinase.
Finally, we analyzed matched samples from CML patients, for the occurrence of BcrAbl and p53 mutations in collaboration with the group of A. Hochhaus in Heidelberg, Germany.
Hans-Guido Wendel 8 We selected patients who were in various disease stages and for whom matched samples, before and after the onset of resistance, were available and who did not have detectable p53 mutations at the start of imatinib therapy. Indeed, upon imatinib resistance we found in 3/5 patients the occurrence of novel p53 mutations and absence of Bcr-Abl mutations; 2 of these p53 mutations were at typical 'hotspot' sites Appendix: Wendel et al., Suppl. Table 1 ). While only a small set, these data indicate that loss of p53 can accompany the onset of imatinib resistance in patients.
In conclusion, we reported that p53, a tumor suppressor that has been implicated in disease progression in CML, contributes to the antitumor activity of imatinib, such that loss of p53 may account, in part for the increase in resistance seen in later disease stages. This study is important because it illustrates that a non-target mutation can mediate resistance to a targeted therapeutic (1) . In fact, our study has sparked similar analyses in solid tumors resistant to EGFR inhibitors. Ultimately, understanding the determinants of response to targeted therapeutics should lead to improved therapies, e.g. combinations.
Completing and publishing the data outlined above has been a priority for me and has to some extent delayed progress on the RNAi screen. However, we have made significant and rather methodical progress towards developing RNAi technology for in vivo screens. Using this vector design we have now conducted some in vitro screens for resistance to chemotherapeutic drugs in lymphoma cells and preliminary data look promising. This has also served to improve the detection technology. Initially, we proposed to use PCR and subsequent sequence analysis to detect enrichment of individual RNAi's. Recently, we had some success using an array-based approach, where a half-hairpin is printed on the chip. Genomic DNA from tumor cells is isolated and the RNAi PCR amplified and subsequently hybridized. This approach
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We are currently conducting in vivo experiments using the p53 RNAi vector as a positive control to reconstruct the library. The purpose of the reconstruction is to define the maximum pool size that will allow identification of a scoring RNAi. These experiments are ongoing and critical as a positive control and to determine pool size.
Overall, the technology for in vivo RNAi screens has presented us with several challenges as outlined above and we have taken a very systematic approach at addressing these problems.
Notably despite tremendous interest, to date no other lab has been able to report an in vivo RNAi screen. We have made significant progress and continue to develop the technology in order to achieve the first in vivo RNAi screen. • Numerous oral and poster presentations at national and international meetings 
CONCLUSION:
We set out to conduct an RNAi screen to identify genetic lesions that might explain the observed increase in imatinib resistance upon progression in CML. The RNAi screen presented us with major technical challenges, which we addressed in a very systematic fashion. In a candidate approach, however, we found that loss of p53, which has been implicated in disease progression in CML, also conferred resistance to imatinib therapy. This finding is surprising, because to date resistance to targeted therapy was almost exclusively attributed to mutations in the direct drug target. We show that a common, non-target mutation can impede targeted therapy. Based on this, other groups are currently looking at the role of p53 loss in solid tumors, e.g. lung cancer, refractory to EGFR inhibitor therapy. Our findings have thus broadened our understanding of the factors determining response to targeted therapy and will hopefully lead to new therapeutic opportunities.
With respect to the RNAi screening technology, we have accomplished important improvements in vector and RNAi design, which come to benefit us and others in our continued effort to use this technology for in vivo screens.
Finally, the collaboration with the Lowe and Hannon labs, in particular in overcoming some of the obstacles in the RNAi project, has been a valuable training experience and presentation and discussion of the work accomplished with the Army sponsorship has enabled me to attain an independent position at Sloan-Kettering.
APPENDIX:

1) Publication:
Wendel, H. G., de Stanchina, E., Cepero, E., Ray, S., Emig, M., Fridman, J. S., Veach, D. R., Bornmann, W. G., Clarkson, B., McCombie, W. R., Kogan, S. C., Hochhaus, A., and Lowe, S. W. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci U S A 2006;103:7444-9. imatinib ͉ mouse model ͉ targeted therapy ͉ drug resistance ͉ tumor-suppressor gene M ost conventional cancer therapies were identified through empirical screens for agents that preferentially kill tumor cells compared with normal tissues. Although these agents are effective in treating some human cancers, many tumors are nonresponsive or evolve to a resistant state. More recently, insights into the molecular basis of cancer have enabled the development of more rational drugs that attack activities involved in the oncogenic process (1). These ''targeted'' therapeutics are often less toxic than conventional drugs and have remarkable activity against some cancers. The effectiveness of such agents may reflect the cancer cell's continued dependency on an oncogenic lesion such that it cannot tolerate the absence of its signal, a phenomenon sometimes referred to as ''oncogene addiction'' (2, 3). However, the molecular determinants that contribute to the sensitivity and resistance of tumor cells to targeted therapies are poorly understood.
2) Supplementary Information:
Imatinib (STI-571, Gleevec) is a small-molecule inhibitor of BCR-ABL whose effectiveness against CML makes it the paradigm for targeted cancer therapy. Clinical resistance to imatinib is most often caused by point mutations in the BCR-ABL kinase that prevent the drug-target interaction and subsequent kinase inhibition (4), an observation that provides formal proof that the BCR-ABL kinase is essential for imatinib sensitivity and that has produced rational strategies to circumvent drug resistance (5, 6) . However, imatinib is generally less effective against Ph ϩ (Philadelphia chromosome) acute lymphoblastic leukemia or CML that has progressed to a more genetically complex phase known as ''blast crisis,'' a response pattern that cannot be entirely explained by the appearance of BCR-ABL mutants (7-9).
Presumably, other factors associated with disease progression can impede imatinib action.
The p53 tumor suppressor provides a potent barrier to tumorigenesis by triggering cell-cycle checkpoints, cellular senescence, or apoptosis in response to DNA damage and aberrant proliferative signals (10, 11) . Because conventional chemotherapeutic agents can exploit the same signaling networks influenced by p53 for their optimal antitumor effects, p53 mutations acquired during tumorigenesis can promote drug resistance as a byproduct of tumor evolution (12) . However, how p53 influences the response of tumors to targeted cancer therapy is not known. Interestingly, p53 mutations can accompany disease progression in human CML (13) (14) (15) (16) (17) , and there is substantial cross-talk between the BCR-ABL and p53 signaling networks (18) (19) (20) (21) (22) . Here, we examine the impact of p53 on the cellular response to imatinib in several well characterized models of BCR-ABLinduced malignant transformation. Our results illustrate how factors linked to malignant progression can modulate the response of tumor cells to targeted cancer therapy and have implications for understanding the heterogeneous responses to these therapies in the clinic.
Results
BCR-ABL Kinase Inhibition Induces p53.
To examine the impact of p53 on imatinib responses in vitro, we first examined Ba͞F3 cells, a murine Pro-B cell line that has been used extensively to study BCR-ABL transformation and imatinib response (5) . Cells were infected with retroviruses expressing a control vector, BCR-ABL (p210), or a BCR-ABL mutant that is insensitive to imatinib (p210͞T315I), and the resulting populations were assessed for p53 levels and BCR-ABL kinase activity 8 h after imatinib addition.
As expected, p53 was expressed at low levels in the parental cells and was not induced after imatinib treatment. In contrast, upon imatinib treatment, p53 was induced in BCR-ABL (p210)-expressing cells but not those expressing the BCR-ABL mutant (T315I). Phosphorylation of p56 DOK-2 , which is a downstream target of BCR-ABL signaling, was high in both BCR-ABLexpressing populations and was repressed in treated cells expressing p210 but not the p210͞T315I mutant (Fig. 1a) . Similar results were observed in 32D cells and after treatment with PD166326, a dual BCR-ABL͞SRC kinase inhibitor with a distinct chemical structure (6) (Fig. 5 , which is published as supporting information on the PNAS web site, and data not shown). However, in a T cell leukemia line expressing BCR-ABL (BV173), significantly higher concentrations of kinase inhibitor were needed to induce p53 levels (e.g., 500 nM PD166326, data not shown), suggesting that cell-line-specific differences can exist (22) .
BCR-ABL promotes oncogenesis through several downstream effectors, including the Akt͞PKB kinase (23) . Akt also phosphorylates Mdm2 on Ser-166, which acts to prevent Mdm2 from efficiently targeting p53 for degradation (24) . Interestingly, phosphorylation of Akt͞PKB was reduced in response to imatinib in p210-expressing BaF͞3 cells, coinciding with a parallel decrease in Ser-166-phosphorylated Mdm2 (Fig. 1b) . Together, these data imply that imatinib activates p53, at least in part, through inhibition of BCR-ABL signaling.
p53 Contributes to Imatinib Action in Vitro. To evaluate the impact of p53 on imatinib action, we used RNA interference (RNAi) to suppress p53 and determined how this RNAi impacted cellular responses to the drug. We introduced a retroviral vector coexpressing one of two different p53 short hairpin (sh)RNAs [p53C (25) and p53D (26) ] with GFP into Ba͞F3 cells expressing p210 or p210͞T315I, and the percentage of GFP positive cells was assessed by flow cytometry. FACS-purified GFP-positive cells expressing the p53 shRNA showed substantial p53 knockdown and prevented p53 induction after imatinib treatment, although BCR-ABL kinase activity was inhibited as indicated by the reduction in phosphorylated p56 Dok-2 protein, a BCR-ABL target (Fig. 1c) . Treatment of the mixed populations with 1 M imatinib revealed that p53 knockdown with either shRNA conferred a selective advantage to Ba͞F3 cells expressing p210, because the fraction of RNAi͞GFP-expressing cells increased substantially (Fig. 1d Upper; and see Fig. 6 , which is published as supporting information on the PNAS web site). By contrast, the RNAi vector targeting p53 conferred no advantage to Ba͞F3 cells expressing the imatinib-resistant p210͞T315I mutant and neither did a control vector (Figs. 1d Lower and 6). Similar results were observed in BCR-ABL-expressing derivatives of the 32D myeloid cell line (see Fig. 7 , which is published as supporting information on the PNAS web site). Thus, p53 can contribute to the antileukemic effects of imatinib in vitro.
We next examined the relationship between p53 and imatinib action in primary cultures enriched for hematopoietic stem cells (HSCs). To this end, we isolated and expanded fetal liver cells derived from crosses of p53 ϩ/Ϫ mice. We transduced these cells with a retroviral vector encoding BCR-ABL and measured p53 expression after imatinib treatment. Similar to our findings in the established Ba͞F3 cell line, we found that in vitro treatment of p53 ϩ/ϩ -enriched HSCs caused decreased activation of Akt and Mdm2 and induction of p53 across a range of imatinib concentrations (Fig. 2a) . To test the impact of imatinib and p53 on the proliferative capacity of these BCR-ABL-expressing hematopoietic progenitors, we performed colony assays in methylcellulose. Here, cells derived from p53 ϩ/ϩ and p53 Ϫ/Ϫ fetal livers were transduced with a BCR-ABL retrovirus that coexpresses GFP such that 15-30% of the population was infected and, thus, expressed both BCR-ABL and GFP. Non-GFP-expressing cells served as an internal control to assess the contribution of BCR-ABL to drug action. Cells were plated in methylcellulose in the presence of various concentrations of imatinib, and colonies were quantified and inspected for GFP fluorescence 10 days later. Consistent with a role for p53 in suppressing BCR-ABL transformation (18) , p53 Ϫ/Ϫ cells produced Ϸ10-fold more BCR-ABL-expressing colonies than the p53 ϩ/ϩ controls (data not shown). As expected, imatinib potently suppressed colony formation by p53 ϩ/ϩ HSCs expressing BCR-ABL with an IC 50 of Ϸ0.05 M. By contrast, p53 Ϫ/Ϫ HSC-expressing BCR-ABL were less sensitive to BCR-ABL inhibition, displaying an increase in IC 50 (IC 50 ϭ 2.1 M) (Fig. 2 b and c) . Interestingly, colony formation by non-BCR-ABL-expressing cells was not substantially influenced by p53 status (IC 50 (p53 ϩ/ϩ ) ϭ 3.2 M, IC 50 (p53 Ϫ/Ϫ ) ϭ 3.8 M) (Fig.  2d) . Therefore, p53 can modulate the cellular effects of oncogene inhibition and contribute to the therapeutic index of imatinib therapy.
p53 Loss Reduces Leukemic Cell Clearance and Survival in Mice
Harboring BCR-ABL Leukemias. We generated mice bearing leukemias of defined p53 status by infecting HSCs derived from p53 ϩ/ϩ , p53 ϩ/Ϫ , and p53 Ϫ/Ϫ fetal livers with a BCR-ABL͞GFP retrovirus transferred into lethally irradiated recipients (Fig. 3a) . Consistent with previous reports (27) , these animals developed a CML-like myeloproliferative disease and, occasionally, an acute leukemia. Although p53 loss did not impact the range of pathologies we observed, the onset of leukemias in mice reconstituted with p53 Ϫ/Ϫ cells was more rapid than controls, and leukemias arising from p53 ϩ/Ϫ cells invariably lost the wild-type p53 allele (Fig. 3 b, c, and Inset) . Still, BCR-ABL-expressing leukemias arising in p53 ϩ/ϩ cells retained an intact p53 pathway, because p53 levels and activity (as measured by expression of its transcriptional target p21) were increased after treatment of leukemia-bearing mice with doxorubicin, a conventional chemotherapeutic agent known to activate p53 (see Fig. 8 , which is published as supporting information on the PNAS web site). Thus, as occurs in other mouse models of BCR-ABL-induced leukemia (28) and in human CML, p53 loss conferred an advantage to BCR-ABL-expressing cells during leukemogenesis.
To test the impact of p53 on imatinib responses in vivo, animals were treated upon leukemia manifestation with a 2-week twicedaily schedule of 100 mg͞kg of body weight imatinib (29) . One cohort of mice was killed at various times after treatment to assess p53 induction and BCR-ABL kinase inhibition, whereas others were monitored for treatment responses by fluorescence imaging or peripheral blood analysis. Consistent with in vitro results, we found an induction of p53 in spleens of leukemic animals but not in normal, nonleukemic mice ( Fig. 4a; Fig. 9a , which is published as supporting information on the PNAS web site; and data not shown). Furthermore, whereas p53 ϩ/ϩ leukemias showed substantial apoptosis in the peripheral blood and were completely cleared, p53 mutant leukemias underwent less apoptosis and only partial responses to imatinib therapy, as determined by blood counts and fluorescence imaging (Figs. 4b  and 9b) .
A cumulative analysis of the treatment data for survival (Fig.  4c ) and time to relapse (see Fig. 10 , which is published as supporting information on the PNAS web site) confirmed a modifying effect of p53 on imatinib response. Although all animals bearing p53-deficient leukemias, generated from either p53 Ϫ/Ϫ or p53 ϩ/Ϫ HSCs, succumbed to their disease by day 25 after the start of imatinib therapy; nearly 40% of animals with p53 ϩ/ϩ leukemias lived beyond this point (Fig. 4c) . Although imatinib clearly has p53-independent activities, these results demonstrate that p53 loss can impede the response to imatinib therapy in vivo.
Imatinib Efficiently Inhibits BCR-ABL Kinase Activity in p53-Deficient
Cells. p53 mutations produce drastic changes in cell physiology and can promote genomic instability (30, 31) . Although it is possible that such secondary changes contribute to the decreased imatinib sensitivity we observe in p53-deficient leukemias, our in vitro data imply that p53 can directly influence cellular responses to imatinib (see Figs. 1 and 2 ). To determine whether p53 loss impairs imatinib action by preventing effective BCR-ABL kinase inhibition (as occurs in cells harboring p210͞T315I) or through a downstream mechanism, we monitored BCR-ABL kinase activity in leukemic bone marrow isolates from imatinib-treated mice. Here, phosphorylation of p56 Dok-2 (a surrogate marker for kinase activity) was repressed within 6 h after a single dose of imatinib, and this repression was sustained for up to 24 h. More (d) Bone marrow lysates of p53 ϩ/ϩ (ϩ) or p53 Ϫ/Ϫ (Ϫ) leukemias were prepared from untreated animals (Untr) or at various times after a single treatment with imatinib and subjected to immunoblotting with antibodies against phosphorylated and total p56 (P-p56, p56) and tubulin (tub).
importantly, p53-expressing and -deficient leukemias showed similar reductions in p56 Dok-2 phosphorylation after imatinib treatment (Fig. 4D) . Therefore, p53 loss does not interfere with the ability of imatinib to inhibit BCR-ABL kinase activity but, instead, attenuates the cellular response to BCR-ABL inhibition.
p53 Mutations Can Accompany Progression to Imatinib Resistance in
Some CML Patients. Our studies use several well characterized models of BCR-ABL transformation to establish that parallel pathways independent from those emanating from the primary oncogenic signal can influence the response to targeted cancer therapy. Although our focus on BCR-ABL and imatinib reflected our desire to study a well characterized model of targeted therapy, our results raise the possibility that these observations may be relevant to human CML. We therefore surveyed a heterogeneous set of 50 specimens from CML patients, most of whom started imatinib in late disease stages and developed hematologic resistance to the drug (8) . Ten resistant samples (20%) had evidence of cytogenetic alterations on chromosome 17, where p53 resides, and 29 (58%) had point mutations in the BCR-ABL kinase domain. Only two resistant specimens showed both BCR-ABL mutations and chromosome 17 abnormalities. However, of the resistant cases that displayed chromosome 17 alterations without BCR-ABL mutations, three of five cases examined by DNA sequence analysis showed p53 mutations that were not present in the preimatinib samples (Table 1 , which is published as supporting information on the PNAS web site). Thus, p53 mutations can accompany progression to imatinib resistance in human CML.
Discussion
We show that disruption of p53 in BCR-ABL-transformed cells can impede sensitivity to imatinib. In contrast to the complete resistance conferred by mutations in the BCR-ABL kinase, p53 loss does not prevent BCR-ABL kinase inhibition but attenuates its antiproliferative effects and modifies imatinib responses in vivo. As a consequence, p53 loss impedes the clearance of leukemic cells, which may increase the population of surviving cells prone to additional progression-and resistance-promoting mutations. In this manner, p53 mutations, or other mutations affecting the p53 network, may contribute to the increase in refractory cases in blast crisis CML or in Ph ϩ (Philadelphia chromosome) acute lymphoblastic leukemia. Such a possibility is consistent with our limited analysis of matched patient samples and clinical data linking p53 mutations to blast crisis and poor outcome and linking an apoptosis-defective p53 variant (Pro-72) to imatinib failure in patients (15, 32) .
Studies in cultured cell lines have noted variable effects of BCR-ABL inhibition on p53 levels and activity (19) (20) (21) (22) . Using BCR-ABL-transformed BaF͞3 cells, primary fetal liver HSCs, and a murine model of CML, we see that, in all cases, p53 is induced in response to imatinib treatment, and, at least in vitro, this finding correlates with a decreased phosphorylation of Akt and Mdm2. Other mechanisms may also contribute to p53 activation after imatinib treatment, including effects of BCR-ABL on Mdm2 translation and checkpoint pathways involved in DNA damage responses (19, 33) . Paradoxically, whereas BCR-ABL kinase inhibition can induce p53 in transformed cells, v-Abl or BCR-ABL expression can induce p53 via the ARF pathway to restrain transformation (ref. 18 ; data not shown). Presumably, BCR-ABL simultaneously induces both pro-and antisurvival signals that impact p53 regulation such that acute ablation of BCR-ABL kinase activity has a greater impact on those signals that restrain p53 action, revealing their antiproliferative potential. Other parallel signaling networks may also impact how a cell responds to BCR-ABL inhibition, thus producing heterogeneity in treatment responses.
The treatment of BCR-ABL-transformed cells with imatinib represents the paradigm of targeted cancer therapy. Irrespective of the overall impact of p53 mutations on response to imatinib therapy in CML patients, our results have implications for the use of targeted therapies in the clinic. For example, we demonstrate that p53 contributes to the dependence of cancer cells on the continued activity of an initiating oncogene, sometimes called oncogene addiction (2) , such that p53 loss attenuates the cellular response to oncogene inactivation. These findings suggest that p53 might contribute to the antitumor activity of other targeted therapeutics, and it is noteworthy that p53 loss facilitates oncogene-independence and the eventual outgrowth of tumors in conditional transgenic mice upon inactivation of the wnt (34) oncogene. Our results also illustrate how mutations that accompany disease progression can reduce the efficacy of targeted therapy, presumably because drug action relies, in part, on genes and processes that normally limit disease progression (e.g., p53). In this view, the response of tumor cells to targeted therapy displays some parallels to conventional therapy, which can also depend on p53 or other stress-response networks for best efficacy. Together, these results may help explain the heterogeneous response of tumors to targeted therapeutics and provide clues for their optimal use. Western Blot Analysis. Immunoblots were performed from wholecell lysates (36) . Antibodies against ␣-tubulin (1:5,000, B-5-1-2; Sigma), p56 and phosphorylated p56 (1:1,000, Cat#s 3914 and 3911; Cell Signaling Technology, Beverly, MA), p53 (1:500, p53-505; NovoCastra, Newcastle upon Tyne, U.K.), p21 (C19, SC-397; Santa Cruz Biotechnology), phosphorylated (Ser-473) Akt (1:1,000, Cat# 4051; Cell Signaling Technology), total Akt (1:1000, Cat# 2966; Cell Signaling Technology), total Mdm2 (clones 2A10 and 4B11 each at 1:50, a gift from A. Levine, Institute for Advanced Study, Princeton) (37), and phosphorylated (ser166) Mdm2 (1:1,000, Cat# 3521; Cell Signaling Technology) were used as probes and detected by using enhanced chemiluminescence.
Materials and Methods
In Vitro Drug-Response Assays. For ''competition'' assays, Ba͞F3͞ p210 or Ba͞F3͞T315I cells were partially transduced with an RNAi vector (p53C or p53D) or a control vector and propagated for 1 week in the presence of absence of 1 M imatinib in standard media. The percentage of GFP-expressing cells was determined by flow cytometry. For methylcellulose assays, fetal liver p53 ϩ/ϩ and p53 Ϫ/Ϫ HSCs (embryonic day 13-15) were derived and retrovirally transduced as described in ref. 35 . Viability was determined by Trypan blue exclusion, and 1 ϫ 10 3 viable cells per well were plated in Methocult GF media (Cat# 3534; StemCell Technologies, Vancouver) in the presence or absence of imatininb. The total number and the number of BCR-ABL͞GFP-expressing colony-forming units were determined 10 days after plating.
Generation of Mice.
The murine model of a retrovirally induced CML-like disease has been described in ref. 27 . We modified the model using fetal liver HSCs (embryonic day 13-15) from a cross of p53 ϩ/Ϫ C57BL͞6 mice. Determination of p53 status was by :q11>q13),der(7)(q?), der(9)t(9;1) (q22p22), del(11)(q23), -16, 
